Kheirollah Yari1, Zohreh Rahimi1,2. 1. Medical Biology Research Center. 2. Department of Clinical Biochemistry, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Abstract
BACKGROUND: We aimed to determine the promoter methylation status of the retinoic acid receptor-beta 2 (RARβ2) gene among breast cancer patients and to review relevant studies in this field in various populations. METHODS: We analyzed 400 samples which comprised blood specimens from 102 breast cancer patients, 102 first-degree female relatives of patients, 100 cancer-free females, 48 breast cancer tissues, and 48 adjacent normal breast tissues from the same patients. The RARβ2 methylation status was determined using methylation-specific polymerase chain reaction (MSP) and DNA sequencing methods. RESULTS: The presence of combined partially methylated (MU) and fully methylated (MM) forms of the RARβ2 gene (MU+MM) in the blood of patients was associated with susceptibility to breast cancer (odds ratio = 4.7, p = 0.05). A significantly higher frequency of the MM genotype was observed in cancer tissue (10.4%) compared to matched adjacent normal breast tissue (0%) (p = 0.02). CONCLUSION: We found a higher frequency of RARβ2 gene methylation in the blood and cancer tissues of patients compared to the blood of controls and adjacent normal breast tissues. The survey of studies on various populations demonstrated a higher RARβ2 methylation frequency in breast cancer patients compared to normal individuals, and many reports suggest a significant association between hypermethylation of the gene and susceptibility to breast cancer.
BACKGROUND: We aimed to determine the promoter methylation status of the retinoic acid receptor-beta 2 (RARβ2) gene among breast cancer patients and to review relevant studies in this field in various populations. METHODS: We analyzed 400 samples which comprised blood specimens from 102 breast cancer patients, 102 first-degree female relatives of patients, 100 cancer-free females, 48 breast cancer tissues, and 48 adjacent normal breast tissues from the same patients. The RARβ2 methylation status was determined using methylation-specific polymerase chain reaction (MSP) and DNA sequencing methods. RESULTS: The presence of combined partially methylated (MU) and fully methylated (MM) forms of the RARβ2 gene (MU+MM) in the blood of patients was associated with susceptibility to breast cancer (odds ratio = 4.7, p = 0.05). A significantly higher frequency of the MM genotype was observed in cancer tissue (10.4%) compared to matched adjacent normal breast tissue (0%) (p = 0.02). CONCLUSION: We found a higher frequency of RARβ2 gene methylation in the blood and cancer tissues of patients compared to the blood of controls and adjacent normal breast tissues. The survey of studies on various populations demonstrated a higher RARβ2 methylation frequency in breast cancer patients compared to normal individuals, and many reports suggest a significant association between hypermethylation of the gene and susceptibility to breast cancer.
Authors: Mohammad O Hoque; Qinghua Feng; Papa Toure; Amadou Dem; Cathy W Critchlow; Stephen E Hawes; Troy Wood; Carmen Jeronimo; Eli Rosenbaum; Joshua Stern; Mujun Yu; Barry Trink; Nancy B Kiviat; David Sidransky Journal: J Clin Oncol Date: 2006-08-14 Impact factor: 44.544
Authors: Ilse Van der Auwera; Catherine Bovie; Cecilia Svensson; Ridha Limame; Xuan B Trinh; Peter van Dam; Steven J Van Laere; Eric Van Marck; Peter B Vermeulen; Luc Y Dirix Journal: Cancer Biol Ther Date: 2009-12-19 Impact factor: 4.742